---
title: PSI vs Parexel
slug_a: appian
slug_b: parexel
site: cro
review_signal_gate: closed
canonical_path: /compare/appian/parexel
generated_by: BioBM Editorial AI
---

# PSI vs Parexel

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

PSI (appian) is listed for cro. PSI runs full-service Phase 2 and 3 clinical trials with a stated focus on on-time enrollment and over 90% repeat and referral business. Key therapeutic areas include oncology, GI, hematology, cell and gene therapy, neurology, and infectious diseases.

Services: 3. Modalities: 3. Indications: 9. Locations: 1. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in indications (9).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Parexel (parexel) is listed for cro. Parexel is a comprehensive CRO offering end-to-end biopharmaceutical development services spanning portfolio optimization, early development, integrated clinical development, regulatory approval, and lifecycle value substantiation.

Services: 17. Modalities: 3. Indications: 12. Locations: 0. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (17).

Review summary: Review summary withheld until site-level review gate opens.